MET Fusion is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 6 are open and 9 are closed. Of the trials that contain MET Fusion and malignant solid tumor as inclusion criteria, 10 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

MET Fusion is an inclusion criterion in 15 clinical trials for non-small cell lung carcinoma, of which 8 are open and 7 are closed. Of the trials that contain MET Fusion and non-small cell lung carcinoma as inclusion criteria, 7 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is phase 3 (0 open) [5].

MET Fusion is an inclusion criterion in 5 clinical trials for hepatocellular carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MET Fusion and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].

MET Fusion is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain MET Fusion and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 3 are phase 1 (2 open) [5].

MET Fusion is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain MET Fusion and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MET Fusion is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 0 are open and 3 are closed. Of the trials that contain MET Fusion and colorectal carcinoma as inclusion criteria, 3 are phase 1 (0 open) [5].

MET Fusion is an inclusion criterion in 3 clinical trials for melanoma, of which 1 is open and 2 are closed. Of the trials that contain MET Fusion and melanoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Fusion and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Fusion and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Fusion and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain MET Fusion and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Fusion and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Fusion and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MET Fusion and lymphoma as inclusion criteria, 2 are phase 1 (0 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Fusion and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Fusion and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MET Fusion and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Fusion and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Fusion and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MET Fusion and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET Fusion is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET Fusion and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [5].